Semax and MOTS-c are two research peptides that occupy entirely different corners of preclinical pharmacology — one a synthetic central-nervous-system heptapeptide derived from the ACTH (4-10) sequence, the other a mitochondrial-derived peptide encoded within the 12S ribosomal RNA region of mitochondrial DNA. Despite being grouped together by researchers exploring “next-generation” peptide tools, they share no target, no pathway, and no mechanism. This page summarizes the structural origin, mechanism of action, and research positioning of each compound for laboratories working in CNS or mitochondrial pharmacology.
Origin: Synthetic Heptapeptide vs Endogenous Mitochondrial Peptide
Semax is a synthetic heptapeptide with the amino acid sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its core (Met-Glu-His-Phe) corresponds to residues 4-7 of adrenocorticotropic hormone (ACTH), with a Pro-Gly-Pro C-terminal extension added during synthesis to confer enzymatic stability and extend the active half-life relative to native ACTH (4-10). Semax was developed within Russian peptide pharmacology research and has been investigated as a research probe for CNS pathways, particularly those involving brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) regulation in rodent models.
MOTS-c (Mitochondrial Open reading frame of the Twelve S rRNA-c) is a 16-amino-acid peptide encoded within the 12S rRNA region of mitochondrial DNA, identified in the published literature out of the Cohen laboratory. Unlike Semax, MOTS-c is not a synthetic analog of a known nuclear-encoded hormone; it is an endogenous mitochondrial-derived peptide (MDP) that has been investigated as a regulator of metabolic homeostasis. Synthetic MOTS-c is supplied for research as a recombinant or solid-phase synthesized peptide.
Mechanism of Action: CNS Pathway vs Metabolic Pathway
Semax has been investigated in the published preclinical literature for its modulation of CNS neurotrophic pathways. Reported research findings have explored the peptide’s tentative role in regulating BDNF and NGF expression in hippocampal and cortical tissue of rodent models, alongside investigations into central monoaminergic systems. The peptide has been characterized as a melanocortin-system-derived research probe, retaining limited melanocortin-receptor activity while operating largely through neurotrophic mechanisms in the published Russian and international literature.
MOTS-c operates through an entirely different mechanism. Published research has investigated MOTS-c as an activator of AMP-activated protein kinase (AMPK) signaling, with downstream effects on metabolic gene expression and folate-methionine-cycle pathway intermediates in cell-based and rodent research models. MOTS-c has been positioned as a research probe for mitochondrial-nuclear cross-talk, exercise-related metabolic adaptation, and AMPK-pathway pharmacology.
Researchers studying CNS peptides may compare Semax with structurally related Selank, another short Russian-origin synthetic peptide investigated for CNS pathway research. Those studying mitochondrial energetics may pair MOTS-c with SLU-PP-332 for ERR-pathway transcriptional comparison.
Semax vs MOTS-c Research Comparison
| Attribute | Semax | MOTS-c |
|---|---|---|
| Origin | Synthetic ACTH (4-10) analog (Russian pharmacology research) | Endogenous mitochondrial-derived peptide (Cohen lab) |
| Sequence | Met-Glu-His-Phe-Pro-Gly-Pro (7 aa) | 16 amino acid peptide encoded in 12S rRNA |
| Encoded by | Synthetic (no endogenous gene) | Mitochondrial DNA (12S rRNA region) |
| Primary research focus | CNS neurotrophic pathway, BDNF/NGF research | AMPK activation, mitochondrial-nuclear cross-talk |
| Receptor class of interest | Melanocortin-derived, neurotrophic signaling | Metabolic kinase signaling (AMPK) |
| Tissue focus in research | Hippocampal, cortical, CNS | Skeletal muscle, adipose, mitochondrial |
| Closest comparator peptide | Selank (Russian-origin CNS peptide) | Humanin, SHLP family (mitochondrial-derived peptides) |
Semax in CNS Pharmacology Research
The published literature on Semax has investigated the heptapeptide as a research tool for studying neurotrophic pathway regulation. Reported preclinical work has examined the influence of Semax administration on BDNF and NGF transcript levels in rodent brain tissue, with additional investigations into central monoaminergic systems including dopaminergic and serotonergic networks. The peptide’s relatively short sequence and Pro-Gly-Pro C-terminal stabilization make it a useful probe for studying short-peptide CNS pharmacology.
Semax has been positioned in Russian-origin literature as a pharmacological research tool with tentative modulatory effects on cognitive-pathway gene expression in preclinical models. As with all preclinical research findings, results are tentative and apply to research models; this page makes no human-use claim of any kind. Investigators may also reference Semax directly or compare against the related research peptide Selank, both of which originate from the same Russian peptide pharmacology lineage.
MOTS-c in Mitochondrial Research
MOTS-c has been characterized in the published literature as a member of the mitochondrial-derived peptide (MDP) family, alongside humanin and the small humanin-like peptide (SHLP) family. The peptide is encoded within the 12S rRNA region of mitochondrial DNA — a non-canonical coding region — and has been investigated for its tentative role as a signaling peptide that crosses from mitochondria to nucleus to influence metabolic gene expression.
Reported preclinical mechanistic findings have explored MOTS-c activation of AMPK signaling, with downstream investigations into folate-methionine-cycle intermediates, glucose handling research in cell-based assays, and exercise-related metabolic adaptation in rodent models. The peptide is supplied as a research-grade lyophilized powder, intended for in vitro and preclinical investigation only.
Investigators studying mitochondrial energetics often pair MOTS-c with research peptides such as MOTS-c for direct sourcing or compare against complementary metabolic compounds in the catalog. Browse the full peptides for sale page for additional research-grade compounds.
Mitochondrial-Derived Peptides as a Research Class
MOTS-c sits within a broader research class of mitochondrial-derived peptides (MDPs) that has expanded substantially in the published literature over the past decade. The class includes humanin (a 24-aa peptide encoded within the 16S rRNA region), the SHLP (small humanin-like peptide) family of six related peptides, and MOTS-c itself. The unifying feature is that all of these are encoded within mitochondrial DNA — a non-canonical coding region — and have been investigated as signaling peptides that influence nuclear gene expression and cellular metabolism.
The discovery and validation of MDPs has reframed parts of mitochondrial biology research from a purely nuclear-encoded protein focus to one that includes mitochondrially-encoded peptide signals. MOTS-c, as one of the better-characterized members of this class, has accordingly attracted research interest as a tool for probing mitochondrial-nuclear cross-talk, AMPK pathway pharmacology, and metabolic gene regulation in cell-based and rodent research models.
Russian Peptide Pharmacology Lineage and Semax
Semax originates from a substantial body of Russian-origin peptide pharmacology research focused on short synthetic peptides as CNS-pathway research tools. The lineage includes related peptides such as Selank (a tuftsin-derived heptapeptide investigated for CNS pathway research) and other short peptides developed within the same research tradition. The published literature on these compounds has investigated central monoaminergic system modulation, BDNF and NGF expression in rodent brain tissue, and tentative effects on cognitive-pathway gene expression in preclinical models.
Researchers approaching Semax research are typically advised to read the foundational Russian-origin publications in translation alongside more recent international preclinical work that has built on those foundations. As with all preclinical research findings, observations are tentative and apply to research models — this page makes no human-use claim of any kind.
Why These Two Are Frequently Confused
Researchers occasionally group Semax and MOTS-c together because both are short peptides outside the mainstream growth-hormone or incretin classes, both are sometimes described as “novel” tools, and both feature in non-traditional preclinical literature. However, the two peptides share no mechanism: Semax is a CNS-focused ACTH-derived heptapeptide, while MOTS-c is a metabolism-focused mitochondrial-derived 16-aa peptide. A research design that selects one over the other should be guided strictly by the experimental question — CNS pathway research versus mitochondrial metabolic research.
Frequently Asked Research Questions
Is Semax derived from ACTH?
Yes. The Met-Glu-His-Phe core of Semax corresponds to residues 4-7 of ACTH, with an added Pro-Gly-Pro C-terminal extension to extend the active half-life. The full sequence is Met-Glu-His-Phe-Pro-Gly-Pro.
Where does MOTS-c come from?
MOTS-c is an endogenous peptide encoded within the 12S rRNA region of mitochondrial DNA, identified in the Cohen laboratory. It is one of the mitochondrial-derived peptide (MDP) family that includes humanin and the SHLP peptides.
What pathway does MOTS-c activate in research?
MOTS-c has been investigated in published literature as an activator of AMP-activated protein kinase (AMPK) signaling, with downstream research into folate-methionine cycle intermediates, glucose handling in cell models, and metabolic gene expression.
Is Semax related to Selank?
Both Semax and Selank are short synthetic peptides from the same Russian peptide pharmacology lineage and both are studied in CNS pathway research, but they have distinct sequences and distinct reported mechanism profiles. Selank is derived from the tuftsin sequence, not ACTH.
Can Semax and MOTS-c be compared head-to-head?
They cannot be meaningfully compared on any shared endpoint because they engage different pathways. Semax research targets CNS neurotrophic signaling; MOTS-c research targets mitochondrial AMPK signaling. They are tools for entirely different research questions.
What purity standard should research Semax and MOTS-c meet?
For quantitative preclinical work, both should meet HPLC-verified purity at or above 99% with per-lot Certificate of Analysis. Proxiva supplies both at 99.9% verified purity with batch-specific COA included with each order.
Source High-Purity Research Peptides
Quality, purity, and provenance directly determine experimental outcomes. Proxiva Peptides supplies all compounds at 99.9% verified purity with HPLC analysis and Certificate of Analysis included on every batch. Browse the full research peptide catalog.
Browse the Full Proxiva Catalog
30+ research peptides · 99.9% HPLC-verified purity · Certificate of Analysis included · Same-day shipping from the United States
All products are for laboratory and research use only. Not for human consumption.